Pulmatrix PE Ratio 2014-2022 | PULM

Current and historical p/e ratio for Pulmatrix (PULM) from 2014 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Pulmatrix PE ratio as of February 03, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Pulmatrix PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-02-03 3.84 0.00
2022-09-30 3.57 $-4.32 0.00
2022-06-30 4.59 $-5.87 0.00
2022-03-31 6.83 $-5.91 0.00
2021-12-31 8.75 $-6.20 0.00
2021-09-30 16.00 $-7.20 0.00
2021-06-30 20.80 $-10.40 0.00
2021-03-31 26.60 $-10.00 0.00
2020-12-31 23.80 $-12.80 0.00
2020-09-30 23.80 $-15.20 0.00
2020-06-30 34.40 $-12.60 0.00
2020-03-31 20.20 $-19.80 0.00
2019-12-31 17.20 $-30.00 0.00
2019-09-30 16.36 $-26.60 0.00
2019-06-30 18.44 $-43.00 0.00
2019-03-31 25.40 $-60.80 0.00
2018-12-31 48.02 $-94.00 0.00
2018-09-30 74.00 $-94.00 0.00
2018-06-30 90.00 $-118.00 0.00
2018-03-31 101.80 $-150.00 0.00
2017-12-31 282.00 $-144.00 0.00
2017-09-30 410.00 $-144.00 0.00
2017-06-30 476.00 $-142.00 0.00
2017-03-31 698.00 $-208.00 0.00
2016-12-31 118.00 $-242.00 0.00
2016-09-30 330.00 $-334.00 0.00
2016-06-30 392.00 $-360.00 0.00
2016-03-31 586.00 $-768.00 0.00
2015-12-31 840.00 $-692.00 0.00
2015-09-30 982.00 $-945.00 0.00
2015-06-30 1920.00 $-1,052.00 0.00
2015-03-31 1720.00 $-700.00 0.00
2014-12-31 1750.00 $-930.00 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.014B $0.005B
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00